[Influence of Co-inhibiting mTORC2 and HSP90 on Proliferation Apoptosis of Multiple Myeloma Cells]

Area of Science:

• Molecular Biology
• Cancer Research
• Pharmacology

Background:

• Multiple Myeloma (MM) is a hematologic malignancy.
• Targeting key signaling pathways like mTORC2 and HSP90 is a strategy in cancer therapy.
• Understanding the interplay between these targets is crucial for novel treatment development.

Purpose of the Study:

• To investigate the combined effect of inhibiting mTORC2 and HSP90.
• To evaluate the impact on proliferation and apoptosis in the U266 multiple myeloma cell line.
• To assess the expression of key proteins involved in cell survival and death.

Main Methods:

• The human MM cell line U266 was cultured and treated with rapamycin (mTORC2 inhibitor) and 17-AAG (HSP90 inhibitor) alone and in combination.
• Phosphate-buffered saline (PBS) served as the control.
• Assessed were growth inhibition rate, morphological changes, apoptosis rate, and expression of caspase 3 and AKT proteins.

Main Results:

• Both rapamycin and 17-AAG inhibited U266 cell growth individually.
• The combination of rapamycin and 17-AAG demonstrated significantly higher growth inhibition and apoptosis induction compared to single agents.
• Combined treatment led to increased caspase 3 and decreased AKT expression, with statistically significant differences (P<0.05).

Conclusions:

• Co-inhibition of mTORC2 and HSP90 effectively suppresses proliferation of multiple myeloma cells.
• This dual inhibition strategy significantly induces apoptosis in MM cells.
• The combination therapy exhibits superior efficacy over single-agent treatments.